Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 86,445,000
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.71
  • Price/Sales 5.38
  • Price/Cash Flow 14.44
  • Price/Book 12.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.89 +3.07%
on 03/08/17
35.92 -5.62%
on 02/23/17
-1.35 (-3.83%)
since 02/22/17
3-Month
32.83 +3.26%
on 02/02/17
37.08 -8.58%
on 01/05/17
-1.64 (-4.61%)
since 12/22/16
52-Week
30.89 +9.74%
on 11/23/16
57.81 -41.36%
on 04/19/16
-20.71 (-37.92%)
since 03/22/16

Most Recent Stories

More News
Smithers Rapra's Extractables & Leachables USA 2017 program features the FDA, Novo Nordisk, NIBRT, Intertek, Boehringer Ingelheim and more

More than 145 extractables and leachables experts from the pharmaceutical industry will convene in Falls Church, VA from May 9-11, 2017 to attend the 9th annual edition of Smithers Rapra's...

NVO : 33.90 (+0.65%)
Registration Now Open for Industry Leading Annual Life Science Career Fair

HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 8th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison,...

NVO : 33.90 (+0.65%)
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays

We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.

NVO : 33.90 (+0.65%)
MRK : 63.50 (-0.64%)
LLY : 84.36 (+0.75%)
SNY : 44.67 (+0.70%)
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - NVO

The following statement is being issued by Levi & Korsinsky, LLP:

NVO : 33.90 (+0.65%)
March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Novo Nordisk A/S Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

Law Offices of Howard G. Smith reminds investors of the upcoming March 13, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors...

NVO : 33.90 (+0.65%)
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline - March 13, 2017

NEW YORK, NY / ACCESSWIRE / March 9, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO)...

NVO : 33.90 (+0.65%)
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - NVO

The following statement is being issued by Levi & Korsinsky, LLP:

NVO : 33.90 (+0.65%)
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA

Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets....

NVO : 33.90 (+0.65%)
MRK : 63.50 (-0.64%)
LLY : 84.36 (+0.75%)
PFE : 34.47 (+0.64%)
NVO Lead Plaintiff Deadline Reminder: Hagens Berman Reminds Novo Nordisk Investors of March 13, 2017 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP reminds investors in Novo Nordisk A/S (NYSE:NVO) of the March 13, 2017 Lead Plaintiff deadline.

NVO : 33.90 (+0.65%)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Novo Nordisk A/S to Contact the Firm Before Imminent Lead Plaintiff Deadline

NEW YORK, NY / ACCESSWIRE / March 5, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) of the March...

NVO : 33.90 (+0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 34.13
1st Resistance Point 34.02
Last Price 33.90
1st Support Level 33.71
2nd Support Level 33.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.